We observed no superior response to DAC, although TP53 mutations were all present in the major clone, and despite other features supporting their disease-driving effect, i.e. TP53-mutated AML only rarely harbored a minor subclone and had a low number of additional mutations [7]. This evidence concerns the gene TP53 and acute myeloid leukemia.